FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...
Vyalev combines foscarbidopa, a prodrug of carbidopa, and foslevodopa, a prodrug of levodopa, into a solution for continuous subcutaneous 24-hour infusion. The Food and Drug Administration (FDA) has ...
High-value acquisition marks Local Infusion's major expansion into South Carolina as Tinsley Medical Practice Brokers strengthens its position as a national leader in medical practice transactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results